Abcam, ab224718, Anti-AIDA antibody [EPR19161] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal AIDA antibody. Carrier free. Suitable for WB and reacts with Mouse samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR19161,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab224718 is the carrier-free version of
ab199323
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The AIDA protein also known as Anisomycin-induced protein A is a little-studied member of a protein family yet plays significant mechanical roles in cellular activities. Its molecular mass is not well characterized but researchers have noted its expression across various tissues notably in the brain and immune cells. The presence in these tissues suggests a versatile and potentially significant function in cellular processes awaiting further exploration.
Biological function summary
The AIDA protein interacts with multiple cellular components to modulate immune responses. It likely forms part of a multi-protein complex orchestrating signaling processes pivotal for cell communication and response. The protein appears to regulate the transcription of certain genes implicated in stress responses offering insights into its possible regulatory roles within cells.
Pathways
AIDA is integrated into the MAPK signaling pathway which is important for transmitting cellular responses to stress stimuli. AIDA interacts with other proteins such as ERK and JNK within this pathway demonstrating its involvement in modulating cellular reactions to external stimuli. This association highlights the dynamic role of AIDA in adapting cellular states to environmental conditions.
AIDA's function relates significantly to neuroinflammatory conditions and immune dysregulation. Its interaction with proteins like NF-kB suggests a role in pathogenesis where chronic inflammation is prevalent such as in multiple sclerosis and rheumatoid arthritis. These associations emphasize the potential of AIDA as a target for therapeutic interventions in inflammatory diseases promising advances for treatment strategies.